Physician profile
Marc Z Handler
NPI 1376854836
$3,610.61
in general payments reported to CMS, 2019-2025
27 companies · $586 in 2025
The $586 reported for 2025 was less than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $56.34 · 2021: $1,096 · 2022: $175 · 2023: $667 · 2024: $789 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,953 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,953.31 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Colgate Oral Pharmaceuticals, INC. | $1,000.00 | 2021 | |
| Abbvie INC. | $464.61 | 2019-2025 | |
| Janssen Biotech, INC. | $316.45 | 2020-2025 | Tremfya |
| Verrica Pharmaceuticals INC. | $242.54 | 2024 | Ycanth |
| Regeneron Healthcare Solutions, INC. | $180.04 | 2023-2025 | Dupixent, Libtayo |
| Incyte Corporation | $159.09 | 2023-2025 | Opzelura |
| Lilly USA, LLC | $158.59 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $156.96 | 2020-2023 | Otezla, Enbrel |
| Sun Pharmaceutical Industries INC. | $156.06 | 2022-2025 | Ilumya, Winlevi |
| Galderma Laboratories, L.P. | $117.74 | 2019-2025 | Nemluvio |
| Leo Pharma INC. | $105.41 | 2022-2025 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $79.70 | 2020-2025 | Cabtreo, Jublia, Arazlo |
| Convatec INC. | $69.02 | 2025 | |
| Mayne Pharma Commercial LLC | $52.46 | 2023-2025 | |
| Celgene Corporation | $43.55 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $43.27 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Epi Health, LLC | $40.62 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $33.37 | 2023-2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $32.69 | 2023 | |
| Genzyme Corporation | $30.99 | 2022-2024 | |
| Medline Industries Lp | $28.75 | 2024 | |
| Organogenesis INC. | $18.36 | 2024 | |
| Pfizer INC. | $17.89 | 2024 | |
| Organon LLC | $16.81 | 2025 | |
| Arcutis Biotherapeutics, INC. | $16.53 | 2025 | Zoryve |
| Dermavant Sciences, INC. | $16.14 | 2024 | Vtama |
| Genentech USA, INC. | $12.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Handler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.